

34
cont.
-- 34. A method according to claim 31 wherein the mGluR5 antagonist is selected from the group consisting of 2-[2-(pyridin-3-yl)ethenyl]-6-methyl-pyridine, 3-methoxy-6-methyl-2-m-tolyethynyl-pyridine, 2-methyl-6-(2,3,5-trichloro-phenylethynyl)-pyridine, 2-methyl-6-(phenylethynyl)-pyridine and 2-(3-fluoro-phenylethynyl)-6-methyl pyridine. --

REMARKS

Claims 1-30 were presented for examination, and Claims 31-34 are now present in the case.

Claims 1-4 have been replaced by "new" Claims 31-34. Support for "new" Claim 31 may be found in "original" Claim 4; support for "new" Claim 32 may be found in the instant specification on Page 2, lines 6-8; support for "new" Claim 33 may be found in the instant specification on Page 2, line 9 to Page 3, line 5; and support for "new" Claim 34 may be found in the instant specification on Page 3, lines 7-9.

Restriction has been required between the following two groups:

Group I – Claims 1-4 directed to a method of treating anxiety and corresponding pharmaceutical compositions.

Group II – Claims 5-30 directed to a method of treating pain and corresponding pharmaceutical compositions.


In response thereto, Applicants respectfully elect the Group I invention, i.e., Claims 1-4 (now Claims 31-34). Accordingly, all of the claims to the non-elected invention of Group II, viz., Claims 5-30, have been cancelled without prejudice to Applicants' right to file one or more divisionals thereon.

In view of the foregoing, an action on the merits of Claims 31-34 is respectfully requested.

Although four "new" claims have been added by this Amendment and Election, thirty claims have been cancelled. Accordingly, no additional fee is necessitated by the added claims.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027



Joseph J. Borovian
Agent for Applicants
Reg. No. 26,631
(908) 522-6921

JJB/ld

Encl.: Postcard

Date: September 17, 2002